Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

NCT04186494 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of the medication liraglutide to a continuous positive airway pressure (CPAP) machine on insulin resistance in adults with obstructive sleep apnea.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 30 people

Who can join Ages 18–60 · all sexes

Timeline Started 2019-12 · est. completion 2022-07

Where 1 site · Ireland

What this study is testing ClinicalTrials.gov NCT04186494 ↗

Description as written by the study sponsor.

This is an explorative, proof-of-concept study exploring the potential therapeutic role of a Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on metabolic parameters, blood pressure, endothelial function, coronary artery calcification, vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to severe obstructive sleep apnea

Treatments tested

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml Drug

GLP-1 analogue treatment in combination with advice on diet and physical exercise
Continuous positive airway pressure treatment Device

Gold standard treatment for obstructive sleep apnea
Liraglutide and CPAP Combination Product

Combination of both treatments

Main thing measured	Insulin resistance
Sponsor	St Vincent's University Hospital, Ireland
Conditions studied	Sleep Apnea, Obstructive
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04186494 ↗